Capitalmind AMC sees pharma resilience, slower IT recovery
In short
Capitalmind AMC said pharma may hold up better, but large IT companies may recover more slowly. It also stayed cautious on consumer stocks because of rate-hike worries.
The comment suggests investors are still focused on the wider economy, even after decent Q2 results. It does not name specific stocks or say when the selling may happen.
What the reporting says
Capitalmind AMC said pharma may remain resilient, while largecap IT could recover more slowly and consumption stocks stay under pressure from rate-hike concerns, according to a publisher summary. The view suggests macro worries are still shaping stock selection despite decent Q2 results. It does not identify specific companies, valuation levels, or a timeline for the expected selling. The immediate consequence is a cautious stance on these sectors.
Why it matters
Anoop Vijaykumar of Capitalmind AMC was cited in a publisher summary saying pharma looks relatively resilient, largecap IT may recover more slowly, and consumption stocks remain exposed to rate-hike worries. The note frames this as macro concerns overshadowing micro-level company results. It offers no stock-specific targets or forecasts, so the practical takeaway is a cautious near-term stance toward those sectors.